Publications by authors named "Joseph Buscema"

Claim this Profile
A
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel.
Matthew A Powell, Line Bjørge, Lyndsay Willmott, Zoltán Novák, Destin Black, Joseph Buscema

Ther Adv Med Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.
Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, Thierry André, Angela Jain, Joseph Buscema

Br J Clin Pharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
Ignace Vergote, Larry J Copeland, Toon Van Gorp, Annouschka Laenen, Giovanni Scambia, Joseph Buscema

Eur J Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
Thomas J Herzog, John B Liao, Karen Finkelstein, Lyndsay Willmott, Wei Duan, Joseph Buscema

Gynecol Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Joseph Buscema

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Matthew A Powell, David Cibula, David M O'Malley, Ingrid Boere, Mark S Shahin, Joseph Buscema

Gynecol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Annika Auranen, Matthew A Powell, Vladyslav Sukhin, Lisa M Landrum, Graziana Ronzino, Joseph Buscema

Ther Adv Med Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Vicky Makker, Jose Alejandro Perez-Fidalgo, Giorgio Valabrega, Erika Hamilton, Toon Van Gorp, Joseph Buscema

Gynecol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Kathleen N Moore, Antoine Angelergues, Gottfried E Konecny, Yolanda García, Susana Banerjee, Joseph Buscema

N Engl J Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Therapy Expenditures Through the First 8 Performance Periods of the Oncology Care Model at a Statewide Multispecialty Health System.
Brian De, Grant Andres, Christine Bates, Edgar Staren, Eric Kutscher, Joseph Buscema

Int J Radiat Oncol Biol Phys· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Thomas J Herzog, John L Hays, Joyce N Barlin, Joseph Buscema, Noelle G Cloven

Future Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Joseph Buscema

N Engl J Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Ursula A Matulonis, Lydia Walder, Trine J Nøttrup, Paul Bessette, Sven Mahner, Joseph Buscema

J Clin Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Gerald Falchook, Robert L Coleman, Andrzej Roszak, Kian Behbakht, Ursula Matulonis, Joseph Buscema

JAMA Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Amit M Oza, Ursula A Matulonis, Susanne Malander, Stacie Hudgens, Jalid Sehouli, Joseph Buscema

Lancet Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignant Female Adnexal Tumor of Probable Wolffian Origin: Case Report and Literature Review.
Shuhui Hong, Jing Cui, Li Li, Joseph Buscema, Casandra Liggins

Int J Gynecol Pathol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Joseph Buscema

N Engl J Med· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer.
Lisa M Hess, Setsuko K Chambers, Kenneth Hatch, Alton Hallum, Mike F Janicek, Joseph Buscema

J Support Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case report of recurrent epithelial ovarian cancer metastatic to the sternum, diaphragm, costae, and bowel managed by aggressive secondary cytoreductive surgery without postoperative chemotherapy.
Arifa Sher-Ahmed, Joseph Buscema, Armando Sardi

Gynecol Oncol· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis